Skip to content

The roles of essential oils in the modulation of immune function: a pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN10793328
Enrollment
20
Registered
2005-09-21
Start date
2005-06-01
Completion date
Unknown
Last updated
2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immunomodulation in smokers/non-smokers Haematological Disorders Immunomodulation in smokers/non-smokers

Interventions

A blend of essential oils, at a total of 10%, in a carrier of unfragranced white lotion base.

Sponsors

Fragrantia Investments (Australia)
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Participants are to be: 1. Aged 18-60 years 2. Male 3. Willing to comply with study protocols 4. The smokers must consume 10 cigarettes per day, and have done so for at least a year 5. The non-smokers must have never smoked

Exclusion criteria

Exclusion criteria: Factors resulting in exclusion include: 1. any significant medical problem or chronic illness including the findings on assessment of: a. Body mass index (BMI) >30 or twice per week) 8. Recreational drug use 9. Any acute illness or infection in the preceding 2 weeks

Design outcomes

Primary

MeasureTime frame
Alterations in the immune system indicators being measured will be estimated via a series of blood tests; the measures include in vivo changes in: 1. Complete blood count including leucocyte count and differential 2. Lymphocyte subset phenotype 3. Natural killer cell activity 4. Erythrocyte sedimentation rate (ESR) 5. C-Reactive protein: high sensitivity assay (hsCRP)

Secondary

MeasureTime frame
Secondary outcome measures include in vivo alterations in: 1. Lymphocyte cytokine production profile 2. Liver function tests 3. Urea, creatinine and electrolytes

Countries

Australia

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026